Product hub: A reproducible and scalable Huntington’s disease human cell model
Senior scientist Dr Tony Oosterveen discusses bit.bio’s new ioDisease Model portfolio, including new models for Huntington’s disease to help advance in vitro research and drug discovery.
What challenge is the industry facing with cell models, in your opinion?
During my scientific career, I have extensively studied how signalling molecules and transcription factors impose an identity on neurons during development of the central nervous system and applied this knowledge to generate different subtypes of dopaminergic neurons from induced pluripotent stem cells (iPSCs). As a senior scientist at bit.bio, I am now using this expertise to develop scalable and defined human neuronal cell models for drug discovery as well as to address fundamental questions in neuroscience.
Related content from this organisation
- MEA to probe ALS phenotypes in neuronal disease models
- Consistent, functional lower motor neurons from iPSCs
- A Molecular Portrait of ALS and FTD
- Application note: Developing next-gen in vitro Huntington’s disease assays
- Right model, right complexity: using in vitro human disease cell models in drug discovery